Navigation Links
ImpactRx Closes Series E Round of Financing
Date:1/11/2010

MT. LAUREL, N.J., Jan. 11 /PRNewswire/ -- ImpactRx® announced today that the company has executed a Series E round of financing in the amount of $1.2 million, of which the first tranche of $678,040 was closed on December 23, 2009. ImpactRx is the pioneering force in measuring the impact of pharmaceutical promotion on the prescribing behavior of the nation's highest value physicians.

"In a year where venture capital investing all but dried up it is rewarding that we could raise investment dollars from our existing investors," said Richard Altus, CEO and President. "The sustained support of ImpactRx by its longstanding investors is a clear acknowledgement of the success achieved by the company over its nine-year history," Altus continued. "To secure this investment in a year like 2009, when the industry faced the challenges of the global recession coupled with the headwinds facing all service providers within the pharmaceutical marketplace, is a vote of confidence in our future," said Altus.

ImpactRx also reported that in 2009 the company's revenues were $28,952,000 which in turn generated free cash flow of $2.2 million prior to any investment activity as compared to free cash of $1.4 million in 2008, representing a 57% increase. In commenting on this achievement, CEO Altus said, "our ability to internally generate incremental cash flow under the very difficult market conditions that existed in 2009 is a real sign of the strength of our business." "The additional funding, coupled with the internally generated free cash flow, will help us expedite our product development and infrastructure improvement plans as well as upgrade our modeling capabilities," continued Altus. "We are investing to accelerate our ability to deliver even more value to our clients," Altus further stated.

"Ending 2009 with a strong balance sheet and no debt, ImpactRx is positioned for high growth and expansion in 2010," Altus concluded.

About ImpactRx

Founded in May 2000, ImpactRx's physician networks coupled with its custom research expertise support an unprecedented intelligence capability for the promotional initiatives of the pharmaceutical industry and for measuring their impact on physician behavior. Based in Mount Laurel, New Jersey, ImpactRx is a private company with investment financing provided by Mediphase Venture Partners (www.mediphaseventure.com), Oxford Bioscience Partners (www.oxbio.com), Merck Capital Ventures, and Omega Funds.


    CONTACT
    Marie Fortier
    ImpactRx, Inc.
    856-273-0221 Ext. 138
    mfortier@impactrx.com



SOURCE ImpactRx


'/>"/>
SOURCE ImpactRx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. comScore Announces Availability of comScore/ImpactRx Physician Behavioral Measurement(TM) Solution
2. ImpactRx Announces Expansion and Addition of Physician Information Networks
3. Senator Landrieu Closes Office: Constituents Turned Away at the Door, Callers Reach Only Busy Signals
4. CapitalSource Closes First Step of Long-Term Care Facility Sale to Omega Healthcare Investors
5. Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical
6. Registration Closes Soon for FDAs Second Annual Science Writers Symposium
7. Augmenix, Inc. Closes $6.1 Million Financing
8. Beckman Coulter Announces Third Quarter 2009 Earnings to be Released on Thursday, October 29, 2009, After Market Closes
9. Archi-Tech Closes the Gap Between Pharmaceutical Managed Care and Primary Sales with Pull-Through Reporting Capabilities
10. Greenway Medical Technologies Closes 11th Consecutive Fiscal Year of Positive Growth
11. AdvanDx Closes $8 Million Financing Round and Elects New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology: